



MAR 28 2006
DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1549

Sheet 1 of 1

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17355-CIP3 (BOT)	SERIAL NO.: 10/757,077
APPLICANT: LANCE E. STEWARD, et al.	TITLE: CLOSTRIDIAL NEUROTOXIN COMPOSITIONS AND MODIFIED CLOSTRIDIAL NEUROTOXINS
FILING DATE: JANUARY 14, 2004	GROUP: 1649

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
		0219462	2003				
RH	AA	2003/219462A1	11/27/2003	STEWART et al.	424	239.1	06/04/2002
RH	AB	2003/027752A1	02/06/2003	STEWART et al.	514	12	07/20/2001
	AC	0027752					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
RH	BA	WO 02/08268A2	01/31/2002	PCT	C07K	14/33	Y
	BB						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

RH	CA	Fernandez-Salas, E., et al., <i>Plasma membrane localization signals in the light chain of botulinum neurotoxin serotype A</i> , Society for Neuroscience Abstract Viewer and Itinerary Planner, Vol. 2003; pages Abstract No. 9.2
	CB	Foran, Patrick G., et al., <i>Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons</i> , Journal of Biological Chemistry, Vol. 278, No. 2, 10 January 2003, pp. 1363-1371
	CC	Wang Xingmin, et al., <i>Genetic analysis of type E botulinum toxin-producing Clostridium butyricum strains</i> , Applied and Environmental Microbiology, vol. 66, no. 11, November 2000, pp. 4992-4997
	CD	Fernandez-Salas, E., et al., <i>Plasma membrane localization signals in the light chain of botulinum neurotoxin</i> , Proceedings of the National Academy of Sciences of the United States of America, 2 March 2004, vol. 101, no. 9, pp. 3208-3213
	CE	
	CF	
	CG	

EXAMINER /Robert Hayes/

DATE CONSIDERED 01/03/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.